Observational studyInternational journal of clinical oncology2026
Long-term progression-free survivors ("super responders") to olaparib maintenance in recurrent ovarian cancer: a multicenter real-world study (KCOG-G2101s).
Naho Fukuda et al.PubMed ↗Publisher ↗
No numbers read from the abstract.